Barriers to glaucoma drug delivery

Journal of Glaucoma

Volumn 17, Issue 2, 2008, Pages 147-156

  Ghate, Deepta ^a   Edelhauser, Henry F ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

Glaucoma drug delivery; Topical medications

Indexed keywords

ACETAZOLAMIDE; ACICLOVIR; ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CEFAZOLIN; CHITOSAN; CIPROFLOXACIN; CYCLODEXTRIN; CYCLOSPORIN A; DIPIVEFRINE; DORZOLAMIDE; DRUG VEHICLE; GENTAMICIN; HYDROCORTISONE; HYDROXYPROPYLMETHYLCELLULOSE; INULIN; LATANOPROST; OFLOXACIN; PHENYLEPHRINE; PILOCARPINE; POLYVINYL ALCOHOL; TIMOLOL; TIMOLOL MALEATE; TRIFLUOROMETHAZOLAMIDE; UNINDEXED DRUG;

ASTHMA; BLURRED VISION; CORNEA EPITHELIUM; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; EDEMA; EYE DISEASE; GLAUCOMA; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

ABSORPTION; ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; VEHICLES;

EID: 40949094794     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31814b990d     Document Type: Review

References (132)

1. Mishima S, Gasset A, Klyce SD Jr, et al. Determination of tear volume and tear flow. Invest Ophthalmo. 1966;5:264-276.
2. Lederer CM Jr, Harold RE. Drop size of commercial glaucoma medications. Am J Ophthalmol. 1986;101:691-694.
3. Patton TF, Francoeur M. Ocular bioavailability and systemic loss of topically applied ophthalmic drugs. Am J Ophthalmol. 1978;85:225-229.
4. Schoenwald RW. Ocular Pharmakokinetics. In: Zimmerman TJ, Ed. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven Publishers; 1997:119-138.
5. Wilson CG, Zhu YP, Kurmala P, et al. Ophthalmic drug delivery. In: Hillery AM, Lloyd AW, eds. Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. New York: Taylor and Francis; 2001:329-354.
6. Van Santvliet L, Ludwig A. Determinants of eye drop size. Surv Ophthalmol. 2004;49:197-213.
7. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207-218.
8. Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol. 1996;121:367-371.
9. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240:430-435.
10. Vuori ML, Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol. 1995;233:131-134.
11. Shedden AH, Laurence J, Barrish A, et al. Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol. 2001;103:73-79.
12. Wilson TW, Firor WB, Johnson GE, et al. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. Clin Pharmacol Ther. 1982;32:676-685.
13. Nieminen T, Uusitalo H, Turjanmaa V, et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol. 2005;61:369-374.
14. Belvisi M. Beta-blocker induced asthma: a role for sensory nerve hyperresponsiveness? Clin Exp Allergy. 1996;26:1343-1346.
15. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134:749-760.
16. Malnick SD, Gelzer G, Attali M. Fatal respiratory arrest following timolol ophthalmic solution. MedGenMed. 2001;3:12.
17. Prince DS, Carliner NH. Respiratory arrest following first dose of timolol ophthalmic solution. Chest. 1983;84:640-641.
18. Chang SC, Lee VH. Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption. J Ocul Pharmacol. 1987;3:159-169.
19. Zimmerman TJ, Sharir M, Nardin GF, et al. Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. Am J Ophthalmol. 1992;114:1-7.
20. Hepsen IF, Yildirim Z, Yilmaz H, et al. Preventive effect of lacrimal occlusion on topical timolol-induced bronchoconstriction in asthmatics. Clin Exp Ophthalmol. 2004;32:597-602.
21. Yamada Y, Takayanagi R, Tsuchiya K, et al. Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther. 2001;17:235-248.
22. Rosenlund EF. The intraocular pressure lowering effect of timolol in gel-forming solution. Acta Ophthalmol Scand. 1996;74:160-162.
23. Ohno Y, Iga T, Yamada Y, et al. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). Curr Eye Res. 2005;30:319-328.
24. Edelhauser HF, Hine JE, Pederson H, et al. The effect of phenylephrine on the cornea. Arch Ophthalmol. 1979;97:937-947.
25. Lass JH, Khosrof SA, Laurence JK, et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol. 1998;116:1003-1010.
26. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403-406.
27. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488.
28. Mindel JS, Smith H, Jacobs M, et al. Drug reservoirs in topical therapy. Invest Ophthalmol Vis Sci. 1984;25:346-350.
29. Maren TH, Jankowska L. Ocular pharmacology of sulfonamides: the cornea as barrier and depot. Curr Eye Res. 1985;4:399-408.
30. Anderson JA, Davis WL, Wei CP. Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of it ocular metabolism with that of the parent compound, epinephrine. Invest Ophthalmol Vis Sci. 1980;19:817-823.
31. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47:S34-S40.
32. Lee VH, Morimoto KW, Stratford RE Jr. Esterase distribution in the rabbit cornea and its implications in ocular drug bioavailability. Biopharm Drug Dispos. 1982;3:291-300.
33. Watsky MA, Jablonski MM, Edelhauser HF. Comparison of conjunctival and corneal surface areas in rabbit and human. Curr Eye Res. 1988;7:483-486.
34. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci. 1985;26:584-587.
35. Ahmed I, Gokhale RD, Shah MV, et al. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci. 1987;76:583-586.
36. Sasaki H, Igarashi Y, Nagano T, et al. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm Res. 1995;12:1146-1150.
37. Kompella UB, Kim KJ, Lee VH. Active chloride transport in the pigmented rabbit conjunctiva. Curr Eye Res. 1993;12:1041-1048.
38. Shi XP, Candia OA. Active sodium and chloride transport across the isolated rabbit conjunctiva. Curr Eye Res. 1995;14:927-935.
39. Marshall WS, Klyce SD. Cellular and paracellular pathway resistances in the "tight" Cl-secreting epithelium of rabbit cornea. J Membr Biol. 1983;73:275-282.
40. Maurice DM. Electrical potential and ion transport across the conjunctiva. Exp Eye Res. 1973;15:527-532.
41. Doane MG, Jensen AD, Dohlman CH. Penetration routes of topically applied eye medications. Am J Ophthalmol. 1978;85:383-386.
42. Olsen TW, Aaberg SY, Geroski DH, et al. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125:237-241.
43. Li SK, Molokhia SA, Jeong EK. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm Res. 2004;21:2175-2184.
44. Bill A. Movement of albumin and dextran throughout the sclera. Arch Ophthalmol. 1965;74:248-252.
45. Olsen TW, Edelhauser HF, Lim JI, et al. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
46. Rudnick DE, Noonan JS, Geroski DH, et al. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci. 1999;40:3054-3058.
47. Baum J, Barza M. Topical vs subconjunctival treatment of bacterial corneal ulcers. Ophthalmology. 1983;90:162-168.
48. Jain MR, Goyal M, Jain V. Ocular penetration of subconjunctivally injected gentamicin, sisomicin and cephaloridine. Jpn J Ophthalmol. 1988;32:392-400.
49. Nagata A, Mishima HK, Kiuchi Y, et al. Binding of antiglaucomatous drugs to synthetic melanin and their hypotensive effects on pigmented and nonpigmented rabbit eyes. Jpn J Ophthalmol. 1993;37:32-38.
50. Menon IA, Trope GE, Basu PK, et al. Binding of timolol to irisciliary body and melanin: an in vitro model for assessing the kinetics and efficacy of long-acting antiglaucoma drugs. J Ocul Pharmacol. 1989;5:313-324.
51. Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol. 1979;23:395-398.
52. Trope GE, Menon IA, Liu GS, et al. Ocular timolol levels after drug withdrawal: an experimental model. Can J Ophthalmol. 1994;29:217-219.
53. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47:S77-S89.
54. Chan T, Payor S, Holden BA. Corneal thickness profiles in rabbits using an ultrasonic pachometer. Invest Ophthalmol Vis Sci. 1983;24:1408-1410.
55. Killey FP, Edelhauser HF, Aaberg TM. Intraocular sulfur hexafluoride and octofluorocyclobutane. Effects on intraocular pressure and vitreous volume. Arch Ophthalmol. 1978;96:511-515.
56. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
57. Cruysberg LP, Nuijts RM, Geroski DH, et al. In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J Ocul Pharmacol Ther. 2002;18:559-569.
58. Forster S, Mead A, Sears M. An interophthalmic communicating artery as explanation for the consensual irritative response of the rabbit eye. Invest Ophthalmol Vis Sci. 1979;18:161-165.
59. Bito LZ. Species differences in the responses of the eye to irritation and trauma: a hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research. Exp Eye Res. 1984;39:807-829.
60. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
61. Anderson DR. Normal Tension Glaucoma Study. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14:86-90.
62. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.
63. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye. 1998;12:234-236.
64. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711-716.
65. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233-236.
66. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17:190-195.
67. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598-606.
68. Edelhauser HF, Maren TH. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthalmol. 1988;106:1110-1115.
69. Maren TH, Jankowska L, Sanyal G, et al. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res. 1983;36:457-479.
70. Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci. 1977;16:1125-1134.
71. Starr MS. Further studies on the effect of prostaglandin on intraocular pressure in the rabbit. Exp Eye Res. 1971;11:170-177.
72. Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol. 1997;41:S61-S68.
73. Giuffre G. The effects of prostaglandin F2 alpha in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985;222:139-141.
74. Prostaglandins and hypotensive lipids. In: Allingham RR, Damji K, Freedman S, et al., eds. Shields Textbook of Glaucoma. Philadelphia: Lippincott-Raven Publishers; 2005:471-483.
75. Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp Eye Res. 1987;44:217-226.
76. Wang RF, Camras CB, Lee PY, et al. Effects of prostaglandins F2 alpha, A2, and their esters in glaucomatous monkey eyes. Invest Ophthalmol Vis Sci. 1990;31:2466-2470.
77. Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134-1145.
78. Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine. Pharm Sci. 1988;77:771-775.
79. Brechue WF, Maren TH. pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci. 1993;34:2581-2587.
80. Conroy CW, Maren TH. Effect of pH on the ocular distribution of a topical carbonic anhydrase inhibitor. Exp Eye Res. 1995;61:213-222.
81. Prinicples of pharmacology in glaucoma. In: Allingham RR, Damji K, Freedman S, et al., eds. Shields Textbook of Glaucoma. Philadelphia: Lippincott-Raven Publishers; 2005:444-456.
82. Katz IM, Hubbard WA, Getson AJ, et al. Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution. Invest Ophthalmol. 1976;15:489-492.
83. Brandt JD, VanDenburgh AM, Chen K, et al, Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023-1031.
84. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47:S6-S12.
85. Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci. 1980;69:391-394.
86. Apt L, Henrick A, Silverman LM. Patient compliance with use of topical ophthalmic corticosteroid suspensions. Am J Ophthalmol. 1979;87:210-214.
87. Diestelhorst M, Kwon KA, Suverkrup R. Dose uniformity of ophthalmic suspensions. J Cataract Refract Surg. 1998;24:672-677.
88. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002;28:353-369.a.
89. Aktas Y, Unlu N, Orhan M, et al. Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine. Drug Dev Ind Pharm. 2003;29:223-230.
90. Maestrelli F, Mura P, Casini A, et al. Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents. J Pharm Sci. 2002;91:2211-2219.
91. Keller N, Moore D, Carper D, et al. Increased corneal permeability induced by the dual effects of transient tear film acidification and exposure to benzalkonium chloride. Exp Eye Res. 1980;30:203-210.
92. Green K, Tonjum A. Influence of various agents on corneal permeability. Am J Ophthalmol. 1971;72:897-905.
93. Pfister RR, Burstein N. The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol. 1976;15:246-259.
94. Gasset AR, Ishii Y, Kaufman He, et al. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol. 1974;78:98-105.
95. Champeau EJ, Edelhauser HF. The effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of Benzalkonium chloride and chlorhexidine digluconate. In: Holly FJ, ed. The Preocular Tear Film in Health, Disease and Contact Lens Wear. Lubbock, TX: Dry eye Institute, Inc; 1986.
96. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
97. Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea. 2006;25:432-437.
98. Patton TF, Robinson JR. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J Pharm Sci. 1975;64:1312-1316.
99. Schenker H, Maloney S, Liss C, et al. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Ther. 1999;21:138-147.
100. March WF, Stewart RM, Mandell AI, et al. Duration of effect of pilocarpine gel. Arch Ophthalmol. 1982;100:1270-1271.
101. Roziere A, Mazuel C, Grove J, et al. Gtelrite: a novel ion activated, in situ gelling polymer for ophthalmic vehicles: effect on bioavailability of Timolol. Int J Pharm. 1989;57:163-168.
102. Ibrahim H, Gurny R, Buri P, et al. Ocular bioavailability of Pilocarpine from phase transition latex system triggered by pH. Eur J Drug Metab Pharmacokinet. 1990;15:206.
103. Ishibashi T, Yokoi N, Bron AJ, et al. Retention of reversibly thermo-gelling timolol on the human ocular surface studied by video meniscometry. Curr Eye Res. 2003;27:117-122.
104. Naveh N, Muchtar S, Benita S. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J Ocul Pharmacol. 1994;10:509-520.
105. Kaswan R. Characteristics of a canine model of KCS: effective treatment with topical cyclosporine. Adv Exp Med Biol. 1994;350:583-594.
106. Gao J, Schwalb TA, Addeo JV, et al. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea. 1998;17:654-663.
107. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000;19:644-649.
108. Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44:247-261.
109. Pflugfelder SC. Integrating restasis into the management of dry eye. Int Ophthalmol Clin. 2006;46:101-103.
110. De Campos AM, Diebold Y, Carvalho EL, et al. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21:803-810.
111. Genta I, Conti B, Perugini P, et al. Bioadhesive microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol. 1997;49:737-742.
112. Di Colo G, Zambito Y, Burgalassi S, et al. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on polyethylene oxide. Int J Pharm. 2002;248:115-122.
113. Kao HJ, Lin HR, Lo YL, et al. Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol. 2006;58:179-186.
114. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005;50:167-182.
115. Vega E, Egea MA, Valls O, et al. Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J Pharm Sci. 2006. [Epub ahead of print August 2.]
116. Irache JM, Merodio M, Arnedo A, et al. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem. 2005;5:293-305.
117. Zimmer A, Mutschler E, Lambrecht G, et al. Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpin nanoparticle-delivery- system. Pharm Res. 1994;11:1435-1442.
118. Chang SW, Chi RF, Wu CC, et al. Benzalkonium chloride and gentamicin cause a leak in corneal epithelial cell membrane. Exp Eye Res. 2000;71:3-10.
119. Grass GM, Wood RW, Robinson JR. Effects of calcium chelating agents on corneal permeability. Invest Ophthalmol Vis Sci. 1985;26:110-113.
120. Sarraf D, Lee DA. The role of iontophoresis in ocular drug delivery. J Ocul Pharmacol. 1994;10:69-81.
121. Halhal M, Renard G, Courtois Y, et al. Iontophoresis: from the lab to the bed side. Exp Eye Res. 2004;78:751-757.
122. Rootman DS, Jantzen JA, Gonzalez JR, et al. Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit. Invest Ophthalmol Vis Sci. 1988;29:1397-1401.
123. Zderic V, Vaezy S, Martin RW, et al. Ocular drug delivery using 20-kHz ultrasound. Ultrasound Med Biol. 2002;28:823-829.
124. Dohlman CH, Pavan-Langston D, Rose J. A new ocular insert device for continuous constant-rate delivery of medication to the eye. Ann Ophthalmol. 1972;4:823-832.
125. Maddox YT, Bernstein HN. An evaluation of the Bionite hydrophilic contact lens for use in a drug delivery system. Ann Ophthalmol. 1972;4:789-790.
126. Sawusch MR, O'Brien TP, Dick JD, et al. Use of collagen corneal shields in the treatment of bacterial keratitis. Am J Ophthalmol. 1988;106:279-281.
127. Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm. 2002;28:621-630.
128. Mundada AS, Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev Ind Pharm. 2006;32:443-448.
129. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47:S41-S52.
130. Kent AR, Nussdorf JD, David R, et al. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology. 2001;108:784-787.
131. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48:S47-S51.
132. Ghate D, Brooks W, McCarey B, et al. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48:2230-2237.